… myeloma cell expression of DEPTOR, an mTOR binding protein that restricts mTOR
activity, suggests an additional future therapeutic target specific to the myeloma tumor model. …

… myeloma cells treated with mTOR inhibitors. Rapamycin enhanced basal AKT activity, AKT
phosphorylation, and PI3K activity in multiple myeloma cells … in multiple myeloma cell AKT …

… inhibitor rapamycin sensitizes multiple myeloma cells to dexamethasone-… myeloma cells
with a mutant 4E-BP1, which is resistant to mTOR-induced phosphorylation, transfected cells …

… Mammalian target of rapamycin inhibitors activate the AKT kinase in multiple myeloma
cells by up-regulating the insulin-like growth factor receptor/insulin receptor substrate-1/…

… sensitized multiple myeloma cells to the antitumor effects of the mammalian target of
rapamycin … myeloma cell lines with an activated AKT allele or empty vector. The AKT-transfected …

… lines, and persistent activation may be important in myeloma cell … myeloma cells, suggesting
that therapeutic strategies that target these pathways may be efficacious in myeloma cells …

… promoter methylation in myeloma cells were altered … myeloma cells when its concentration
was increased to 10 µM. Investigation of the effect of curcumin on normal bone marrow cells …

Multiple myeloma (MM) is the second most common hematological malignancy and results
from the clonal amplification of plasma cells. Despite recent advances in treatment, MM …

… B-cell differentiation. IKZF3 regulates IRF4 expression, a master regulator of an aberrant
myeloma-… Lenalidomide exerts its activity in myeloma cells through binding to cereblon (CRBN) …

… myeloma cells with the targeted vector coding for the human sodiumiodide symporter (hNIS)
led to hNIS expression by these cells … be transcriptionally targeted for myeloma cells and the …